Sentences with phrase «on cancer drugs»

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

But in November, Geron announced that it was halting its trial to focus instead on cancer drugs.

The company focuses on cancer drug research and has a platform for so - called «real - world» data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.

Watson thought the center would focus on cancer drug discovery.

Several years ago, for example, poor chemical probe data led researchers to pursue a final stage clinical trial on a cancer drug candidate called iniparib.

Assisted with project on cancer drug and DNA interactions led by two faculty members at UNH and three at other institutions in New England

Not exact matches

Drugmaker Merck reported a better - than - expected first - quarter profit on Tuesday, helped by a more than 150 percent rise in sales of cancer drug Keytruda.

Darzalex, however, has not yet reached its peak potential as the drug moves into earlier stages of the disease and is being tested on solid tumours like lung cancer.

The Food and Drug Administration (FDA) on Tuesday gave Swiss drug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancDrug Administration (FDA) on Tuesday gave Swiss drug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancdrug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancers.

Genmab has morphed from a cash - burning operation into a profitable business especially due to the success of blood cancer drug Darzalex, on which it is paid a royalty of 12 to 20 percent on sales of the drug.

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

It's the first time the agency has approved a drug that targets cancer based on a tumor's genetic traits, rather than where it is located in the body.

The Hong Kong - listed company has two blockbuster drugs on its roster — anlotinib for lung cancer and tenofovir for hepatitis B — and a few blockbuster generics aiming for approval before 2021.

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

Cancer patients, especially those on chemotherapy, can really benefit from a personal chef who knows how to make food that's especially appealing when chemotherapy drugs make food unappealing but when it is important to maintain nutrition for strength and the best health possible.

The biotech received Food and Drug Administration (FDA) approval for its drug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on TuesDrug Administration (FDA) approval for its drug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on Tuesdrug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on Tuesday.

The falling rate of cancer - related deaths is clearly an impressive achievement, and may be partially attributable to drug makers» increased focus on developing novel new therapies to fight cancers.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

On Wednesday, Swiss pharmaceutical giant Novartis made history as the first company to win Food and Drug Administration (FDA) approval for a groundbreaking new type of cancer treatment known as CAR - T.

The drug may soon find a wider market if it can be shown effective in treating lymphoma and other blood cancers, and the price for those indications may well be different, based on their if value story.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

In the last of those years, the reporters discovered, the federal government actually spent more on urine - based drug tests than it did on «the four most recommended cancer screenings combined.»

The study, just published in Science, showed that the creation of what the researchers are calling microtumors can help predict drug effectiveness in cancer patients better than the current standard method of testing the drugs on rodents.

Gilead CEO John Milligan speaks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about the company's M&A outlook, drug pricing and their work on cancer and Hepatitis C treatments.

Ligand gets royalties on sales of Amgen's Kyprolis drug, which treats a form of incurable blood cancer.

Doctors and hospitals spend more than $ 90 million each year on cancer - fighting drugs.

So when a venture capitalist called last fall asking her to lead a small cancer startup, she jumped at the opportunity to focus on a single drug — with no bureaucracy or politics.

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

«The situation with the number of cancer drugs on the market has improved since then,» Jensen said.

Drug giant Johnson & Johnson has been hit with a $ 417 million verdict in the latest trial focusing on alleged links between talc - based products like its Johnson's Baby Powder, use by many for feminine hygiene, and ovarian cancer.

The Finnish drug maker on Sunday presented results from phase I trial of a prostate cancer treatment, saying according the data it «has been well tolerated, with no significant treatment - related adverse events.»

Fortune spoke with Brad Loncar, an independent biotech investor who launched the first - ever cancer immunotherapy index fund last year, about the biggest winners out of ASCO and which cancer drug hopefuls you should keep an eye on going forward.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therDrug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therdrug for a new kind of cancer treatment called CAR - T cell therapy.

Analysts have said that the company could make for a good acquisition, but more data on its cancer immunotherapy drugs may need to come in first.

So, Loncar took matters into his own hands and created a new type of biotech index that focuses exclusively on the red - hot field of cancer immunotherapy drugs (treatments which use the body's immune system as a conduit to fight cancer).

PERTH - based Medi - tech Research Limited may be on the brink of a major advance in cancer therapy with its hyaluronic acid technology for the delivery of anti-cancer drugs.

Merck — Merck was upgraded to «buy» from «neutral» at Goldman Sachs and added to Goldman's «Conviction Buy» list, based on Merck's success with its cancer drug Keytruda.

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)- Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research.

New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new - generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.

HERERA: Merck (NYSE: MRK) was one of the best performing stocks on the blue chip Dow index today, after the drug company «s new type of lung cancer drug performed better than expected in a highly anticipated clinical trial.

Additional clinical trial data later this year on Tesaro's key drug, Niraparib, which targets advanced solid tumors in ovarian and breast cancers, could help narrow the valuation gap, the people said.

Eli Lilly and Co lifted its full - year profit forecast on Tuesday after comfortably beating estimates for the first quarter, largely due to strong sales of its diabetes and cancer drugs and lower expenses.

SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early - stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

ZURICH (Reuters)- Roche's Tecentriq immuno - oncology drug failed a late - stage follow - up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine.

Roche, the world's biggest maker of cancer drugs, had won fast - track approval last May in the United States for Tecentriq against bladder cancer but full approval hinged on further trials.

U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno - oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA.

They have instead offered concessions like raising caps on foreign investors» stakes in Chinese financial institutions, and proposed eliminating import tariffs in narrow categories like drugs to treat cancer.

(Reuters)- Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $ 12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.